{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:48:27Z","timestamp":1793886507009,"version":"4.8.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04188-4","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:48:00Z","timestamp":1769518080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mechanisms and intervention strategies of microenvironment-mediated drug resistance in multiple myeloma"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhu","family":"Xiaoling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tingting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Meijia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"4188_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. https:\/\/doi.org\/10.1038\/nrdp.2017.46.","journal-title":"Nat Rev Dis Primers"},{"key":"4188_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10:45. https:\/\/doi.org\/10.1038\/s41572-024-00529-7.","journal-title":"Nat Rev Dis Primers"},{"key":"4188_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28515-1","volume":"13","author":"YLD Ng","year":"2022","unstructured":"Ng YLD, et al. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat Commun. 2022;13:1009. https:\/\/doi.org\/10.1038\/s41467-022-28515-1.","journal-title":"Nat Commun"},{"key":"4188_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.973836","volume":"12","author":"AG Solimando","year":"2022","unstructured":"Solimando AG, et al. Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche. Front Oncol. 2022;12:973836. https:\/\/doi.org\/10.3389\/fonc.2022.973836.","journal-title":"Front Oncol"},{"key":"4188_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.899272","volume":"12","author":"J Schwestermann","year":"2022","unstructured":"Schwestermann J, Besse A, Driessen C, Besse L. Contribution of the tumor microenvironment to metabolic changes triggering resistance of multiple myeloma to proteasome inhibitors. Front Oncol. 2022;12:899272. https:\/\/doi.org\/10.3389\/fonc.2022.899272.","journal-title":"Front Oncol"},{"key":"4188_CR6","doi-asserted-by":"publisher","first-page":"9535","DOI":"10.3390\/curroncol29120749","volume":"29","author":"C Chakraborty","year":"2022","unstructured":"Chakraborty C, Mukherjee S. Molecular crosstalk between chromatin remodeling and tumor microenvironment in multiple myeloma. Curr Oncol. 2022;29:9535\u201349. https:\/\/doi.org\/10.3390\/curroncol29120749.","journal-title":"Curr Oncol"},{"key":"4188_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/14737140.2023.2229029","volume":"23","author":"H Yao","year":"2023","unstructured":"Yao H, et al. Role of the bone marrow microenvironment in multiple myeloma treatment using CAR-T therapy. Expert Rev Anticancer Ther. 2023;23:807\u201315. https:\/\/doi.org\/10.1080\/14737140.2023.2229029.","journal-title":"Expert Rev Anticancer Ther"},{"key":"4188_CR8","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","volume":"32","author":"O Bruck","year":"2018","unstructured":"Bruck O, et al. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia. 2018;32:1643\u201356. https:\/\/doi.org\/10.1038\/s41375-018-0175-0.","journal-title":"Leukemia"},{"key":"4188_CR9","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1080\/10428194.2022.2056175","volume":"63","author":"AA Mangaonkar","year":"2022","unstructured":"Mangaonkar AA, Patnaik MM. Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation. Leuk Lymphoma. 2022;63:1792\u2013800. https:\/\/doi.org\/10.1080\/10428194.2022.2056175.","journal-title":"Leuk Lymphoma"},{"key":"4188_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11899-015-0283-0","volume":"10","author":"R Karp Leaf","year":"2015","unstructured":"Karp Leaf R, Cho HJ, Avigan D. Immunotherapy for multiple myeloma, past, present, and future: monoclonal antibodies, vaccines, and cellular therapies. Curr Hematol Malig Rep. 2015;10:395\u2013404. https:\/\/doi.org\/10.1007\/s11899-015-0283-0.","journal-title":"Curr Hematol Malig Rep"},{"key":"4188_CR11","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.3390\/curroncol29110705","volume":"29","author":"M Ho","year":"2022","unstructured":"Ho M, Xiao A, Yi D, Zanwar S, Bianchi G. Treating multiple myeloma in the context of the bone marrow microenvironment. Curr Oncol. 2022;29:8975\u20139005. https:\/\/doi.org\/10.3390\/curroncol29110705.","journal-title":"Curr Oncol"},{"key":"4188_CR12","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1016\/j.clml.2020.05.026","volume":"20","author":"M Ho","year":"2020","unstructured":"Ho M, et al. Role of the bone marrow milieu in multiple myeloma progression and therapeutic resistance. Clin Lymphoma Myeloma Leuk. 2020;20:e752\u201368. https:\/\/doi.org\/10.1016\/j.clml.2020.05.026.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4188_CR13","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3892\/ijo.2014.2652","volume":"45","author":"K Sadahira","year":"2014","unstructured":"Sadahira K, et al. Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2\/Mcl-1 pathway. Int J Oncol. 2014;45:2278\u201386. https:\/\/doi.org\/10.3892\/ijo.2014.2652.","journal-title":"Int J Oncol"},{"key":"4188_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.exphem.2016.09.009","volume":"45","author":"M Park","year":"2017","unstructured":"Park M, et al. Alterations in the bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia, and normal bone marrow. Exp Hematol. 2017;45:56\u201363. https:\/\/doi.org\/10.1016\/j.exphem.2016.09.009.","journal-title":"Exp Hematol"},{"key":"4188_CR15","doi-asserted-by":"publisher","unstructured":"Katagiri T et al. Distinct effects of chondroitin sulfate on hematopoietic cells and the stromal microenvironment in bone marrow hematopoiesis. Exp Hematol 96, 52\u201362 e55. https:\/\/doi.org\/10.1016\/j.exphem.2021.02.003 (2021).","DOI":"10.1016\/j.exphem.2021.02.003"},{"key":"4188_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010025","author":"M Ichii","year":"2020","unstructured":"Ichii M, Hosen N. Current understanding of myelomatous mesenchymal stromal cells extended through advances in experimental methods. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers13010025.","journal-title":"Cancers (Basel)"},{"key":"4188_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03741-x","volume":"25","author":"S Kamrani","year":"2025","unstructured":"Kamrani S, et al. Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword. Cancer Cell Int. 2025;25:117. https:\/\/doi.org\/10.1186\/s12935-025-03741-x.","journal-title":"Cancer Cell Int"},{"key":"4188_CR18","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3324\/haematol.2019.239913","volume":"106","author":"AG Solimando","year":"2021","unstructured":"Solimando AG, et al. Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. Haematologica. 2021;106:1943\u201356. https:\/\/doi.org\/10.3324\/haematol.2019.239913.","journal-title":"Haematologica"},{"key":"4188_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.608815","volume":"10","author":"T Chen","year":"2020","unstructured":"Chen T, Moscvin M, Bianchi G. Exosomes in the pathogenesis and treatment of multiple myeloma in the context of the bone marrow microenvironment. Front Oncol. 2020;10:608815. https:\/\/doi.org\/10.3389\/fonc.2020.608815.","journal-title":"Front Oncol"},{"key":"4188_CR20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s12185-023-03579-x","volume":"117","author":"BM Russell","year":"2023","unstructured":"Russell BM, Avigan DE. Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy. Int J Hematol. 2023;117:652\u20139. https:\/\/doi.org\/10.1007\/s12185-023-03579-x.","journal-title":"Int J Hematol"},{"key":"4188_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040988","author":"LC Holthof","year":"2020","unstructured":"Holthof LC, Mutis T. Challenges for immunotherapy in multiple myeloma: bone marrow microenvironment-mediated immune suppression and immune resistance. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12040988.","journal-title":"Cancers (Basel)"},{"key":"4188_CR22","doi-asserted-by":"publisher","first-page":"782","DOI":"10.2174\/1568009617666170214103834","volume":"17","author":"K Podar","year":"2017","unstructured":"Podar K, Jager D. Targeting the immune niche within the bone marrow microenvironment: the rise of immunotherapy in multiple myeloma. Curr Cancer Drug Targets. 2017;17:782\u2013805. https:\/\/doi.org\/10.2174\/1568009617666170214103834.","journal-title":"Curr Cancer Drug Targets"},{"key":"4188_CR23","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3892\/or.2016.4987","volume":"36","author":"F Liu","year":"2016","unstructured":"Liu F, et al. Fucoidan inhibits angiogenesis induced by multiple myeloma cells. Oncol Rep. 2016;36:1963\u201372. https:\/\/doi.org\/10.3892\/or.2016.4987.","journal-title":"Oncol Rep"},{"key":"4188_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.blre.2016.04.002","volume":"30","author":"E Malek","year":"2016","unstructured":"Malek E, et al. Myeloid-derived suppressor cells: the green light for myeloma immune escape. Blood Rev. 2016;30:341\u20138. https:\/\/doi.org\/10.1016\/j.blre.2016.04.002.","journal-title":"Blood Rev"},{"key":"4188_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.909880","volume":"13","author":"R Lopes","year":"2022","unstructured":"Lopes R, et al. Multiple myeloma-derived extracellular vesicles modulate the bone marrow immune microenvironment. Front Immunol. 2022;13:909880. https:\/\/doi.org\/10.3389\/fimmu.2022.909880.","journal-title":"Front Immunol"},{"key":"4188_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10585-014-9652-7","volume":"31","author":"R Khan","year":"2014","unstructured":"Khan R, et al. Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression. Clin Exp Metastasis. 2014;31:585\u201393. https:\/\/doi.org\/10.1007\/s10585-014-9652-7.","journal-title":"Clin Exp Metastasis"},{"key":"4188_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2020.111004","volume":"113","author":"X Wang","year":"2020","unstructured":"Wang X, Xu J, Xu X, Fang Q, Tang R. Ph-sensitive bromelain nanoparticles by ortho ester crosslinkage for enhanced doxorubicin penetration in solid tumor. Mater Sci Eng C Mater Biol Appl. 2020;113:111004. https:\/\/doi.org\/10.1016\/j.msec.2020.111004.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"4188_CR28","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1111\/febs.12179","volume":"280","author":"A Skliris","year":"2013","unstructured":"Skliris A, et al. Cell-surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases. FEBS J. 2013;280:2342\u201352. https:\/\/doi.org\/10.1111\/febs.12179.","journal-title":"FEBS J"},{"key":"4188_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijpharm.2015.01.039","volume":"482","author":"N Sasaki","year":"2015","unstructured":"Sasaki N, Bos C, Escoffre JM, Storm G, Moonen C. Development of a tumor tissue-mimicking model with endothelial cell layer and collagen gel for evaluating drug penetration. Int J Pharm. 2015;482:118\u201322. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.01.039.","journal-title":"Int J Pharm"},{"key":"4188_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.actbio.2020.04.051","volume":"113","author":"RP Mohanty","year":"2020","unstructured":"Mohanty RP, Liu X, Ghosh D. Electrostatic driven transport enhances penetration of positively charged peptide surfaces through tumor extracellular matrix. Acta Biomater. 2020;113:240\u201351. https:\/\/doi.org\/10.1016\/j.actbio.2020.04.051.","journal-title":"Acta Biomater"},{"key":"4188_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21020613","author":"R Ria","year":"2020","unstructured":"Ria R, Vacca A. Bone marrow stromal cells-induced drug resistance in multiple myeloma. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21020613.","journal-title":"Int J Mol Sci"},{"key":"4188_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/bs.ircmb.2014.10.004","volume":"314","author":"D Ribatti","year":"2015","unstructured":"Ribatti D, Nico B, Vacca A. Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis. Int Rev Cell Mol Biol. 2015;314:259\u201382. https:\/\/doi.org\/10.1016\/bs.ircmb.2014.10.004.","journal-title":"Int Rev Cell Mol Biol"},{"key":"4188_CR33","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1038\/onc.2011.412","volume":"31","author":"S Berardi","year":"2012","unstructured":"Berardi S, et al. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. Oncogene. 2012;31:2258\u201369. https:\/\/doi.org\/10.1038\/onc.2011.412.","journal-title":"Oncogene"},{"key":"4188_CR34","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s44318-024-00078-5","volume":"43","author":"J Zhu","year":"2024","unstructured":"Zhu J, et al. Pericyte signaling via soluble guanylate cyclase shapes the vascular niche and microenvironment of tumors. EMBO J. 2024;43:1519\u201344. https:\/\/doi.org\/10.1038\/s44318-024-00078-5.","journal-title":"EMBO J"},{"key":"4188_CR35","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ajpath.2011.11.029","volume":"180","author":"K Akiyama","year":"2012","unstructured":"Akiyama K, et al. Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol. 2012;180:1283\u201393. https:\/\/doi.org\/10.1016\/j.ajpath.2011.11.029.","journal-title":"Am J Pathol"},{"key":"4188_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj4678","volume":"10","author":"F Yang","year":"2024","unstructured":"Yang F, et al. An immunosuppressive vascular niche drives macrophage polarization and immunotherapy resistance in glioblastoma. Sci Adv. 2024;10:eadj4678. https:\/\/doi.org\/10.1126\/sciadv.adj4678.","journal-title":"Sci Adv"},{"key":"4188_CR37","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.2147\/CMAR.S172261","volume":"10","author":"C Jiang","year":"2018","unstructured":"Jiang C, et al. Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer. Cancer Manag Res. 2018;10:3589\u201397. https:\/\/doi.org\/10.2147\/CMAR.S172261.","journal-title":"Cancer Manag Res"},{"key":"4188_CR38","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12957","volume":"22","author":"X Sun","year":"2021","unstructured":"Sun X, Chen Z. Cancer-associated fibroblast-derived CCL5 contributes to cisplatin resistance in A549 NSCLC cells partially through upregulation of lncRNA HOTAIR expression. Oncol Lett. 2021;22:696. https:\/\/doi.org\/10.3892\/ol.2021.12957.","journal-title":"Oncol Lett"},{"key":"4188_CR39","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41598-020-57698-0","volume":"10","author":"H Xie","year":"2020","unstructured":"Xie H, et al. Silencing of SENP2 in multiple myeloma induces bortezomib resistance by activating NF-kappaB through the modulation of IkappaBalpha sumoylation. Sci Rep. 2020;10:766. https:\/\/doi.org\/10.1038\/s41598-020-57698-0.","journal-title":"Sci Rep"},{"key":"4188_CR40","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1080\/10428194.2018.1493727","volume":"60","author":"K Cai","year":"2019","unstructured":"Cai K, et al. Targeting the cross-talk between the Hedgehog and NF-kappaB signaling pathways in multiple myeloma. Leuk Lymphoma. 2019;60:772\u201381. https:\/\/doi.org\/10.1080\/10428194.2018.1493727.","journal-title":"Leuk Lymphoma"},{"key":"4188_CR41","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-12-0779","volume":"18","author":"C Fabre","year":"2012","unstructured":"Fabre C, et al. Dual inhibition of canonical and noncanonical NF-\u03baB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012;18:4669\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0779.","journal-title":"Clin Cancer Res"},{"key":"4188_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bjh.12734","volume":"165","author":"F Azab","year":"2014","unstructured":"Azab F, et al. PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance. Br J Haematol. 2014;165:89\u2013101. https:\/\/doi.org\/10.1111\/bjh.12734.","journal-title":"Br J Haematol"},{"key":"4188_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/10781552211035369","volume":"28","author":"M Mehdizadeh","year":"2022","unstructured":"Mehdizadeh M, et al. Phosphatidylinositol 3-kinase signaling inhibitors for treatment of multiple myeloma: from small molecules to micrornas. J Oncol Pharm Pract. 2022;28:149\u201358. https:\/\/doi.org\/10.1177\/10781552211035369.","journal-title":"J Oncol Pharm Pract"},{"key":"4188_CR44","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.2174\/0929867321666140601204513","volume":"21","author":"J Zhu","year":"2014","unstructured":"Zhu J, Wang M, Cao B, Hou T, Mao X. Targeting the phosphatidylinositol 3-kinase\/AKT pathway for the treatment of multiple myeloma. Curr Med Chem. 2014;21:3173\u201387. https:\/\/doi.org\/10.2174\/0929867321666140601204513.","journal-title":"Curr Med Chem"},{"key":"4188_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155401","volume":"260","author":"M Alimohammadi","year":"2024","unstructured":"Alimohammadi M, et al. A comprehensive review of the PTEN\/PI3K\/Akt axis in multiple myeloma: from molecular interactions to potential therapeutic targets. Pathol Res Pract. 2024;260:155401. https:\/\/doi.org\/10.1016\/j.prp.2024.155401.","journal-title":"Pathol Res Pract"},{"key":"4188_CR46","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"key":"4188_CR47","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.immuni.2018.03.037","volume":"48","author":"K Ganesh","year":"2018","unstructured":"Ganesh K, Massague J. TGF-beta inhibition and immunotherapy: checkmate. Immunity. 2018;48:626\u20138. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.037.","journal-title":"Immunity"},{"key":"4188_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121892","author":"FM Uckun","year":"2019","unstructured":"Uckun FM, Qazi S, Hwang L, Trieu VN. Recurrent or refractory high-grade gliomas treated by convection-enhanced delivery of a TGF\u03b22-targeting RNA therapeutic: a post-hoc analysis with long-term follow-up. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11121892.","journal-title":"Cancers (Basel)"},{"key":"4188_CR49","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538\u201343. https:\/\/doi.org\/10.1038\/nature25492.","journal-title":"Nature"},{"key":"4188_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1059715","volume":"10","author":"PS Rana","year":"2022","unstructured":"Rana PS, Soler DC, Kort J, Driscoll JJ. Targeting TGF-\u03b2 signaling in the multiple myeloma microenvironment: steering CARs and T cells in the right direction. Front Cell Dev Biol. 2022;10:1059715. https:\/\/doi.org\/10.3389\/fcell.2022.1059715.","journal-title":"Front Cell Dev Biol"},{"key":"4188_CR51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10238-018-0531-4","volume":"19","author":"K Mashimo","year":"2019","unstructured":"Mashimo K, et al. RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells. Clin Exp Med. 2019;19:133\u201341. https:\/\/doi.org\/10.1007\/s10238-018-0531-4.","journal-title":"Clin Exp Med"},{"key":"4188_CR52","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbrc.2012.10.071","volume":"428","author":"D Xu","year":"2012","unstructured":"Xu D, et al. Dll1\/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochem Biophys Res Commun. 2012;428:518\u201324. https:\/\/doi.org\/10.1016\/j.bbrc.2012.10.071.","journal-title":"Biochem Biophys Res Commun"},{"key":"4188_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094462","author":"N Giannakoulas","year":"2021","unstructured":"Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22094462.","journal-title":"Int J Mol Sci"},{"key":"4188_CR54","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1158\/1078-0432.CCR-20-2839","volume":"27","author":"F Fontana","year":"2021","unstructured":"Fontana F, et al. VLA4-targeted nanoparticles hijack cell adhesion-mediated drug resistance to target refractory myeloma cells and prolong survival. Clin Cancer Res. 2021;27:1974\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2839.","journal-title":"Clin Cancer Res"},{"key":"4188_CR55","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2141.2011.08794.x","volume":"155","author":"M Mraz","year":"2011","unstructured":"Mraz M, et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol. 2011;155:53\u201364. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08794.x.","journal-title":"Br J Haematol"},{"key":"4188_CR56","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","volume":"119","author":"AK Azab","year":"2012","unstructured":"Azab AK, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012;119:1468\u201378. https:\/\/doi.org\/10.1182\/blood-2011-07-368050.","journal-title":"Blood"},{"key":"4188_CR57","doi-asserted-by":"publisher","first-page":"19702","DOI":"10.1002\/jcp.28570","volume":"234","author":"Y Liu","year":"2019","unstructured":"Liu Y, Liang HM, Lv YQ, Tang SM, Cheng P. Blockade of SDF-1\/CXCR4 reduces adhesion-mediated chemoresistance of multiple myeloma cells via interacting with interleukin-6. J Cell Physiol. 2019;234:19702\u201314. https:\/\/doi.org\/10.1002\/jcp.28570.","journal-title":"J Cell Physiol"},{"key":"4188_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01031-3","volume":"14","author":"Z Ren","year":"2021","unstructured":"Ren Z, et al. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma. J Hematol Oncol. 2021;14:11. https:\/\/doi.org\/10.1186\/s13045-021-01031-3.","journal-title":"J Hematol Oncol"},{"key":"4188_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143461","author":"Z Matula","year":"2021","unstructured":"Matula Z. Stromal cells serve drug resistance for multiple myeloma via mitochondrial transfer: a study on primary myeloma and stromal cells. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13143461.","journal-title":"Cancers (Basel)"},{"key":"4188_CR60","doi-asserted-by":"publisher","first-page":"616580","DOI":"10.3389\/fcell.2021.616580","volume":"9","author":"Q Yu","year":"2021","unstructured":"Yu Q, et al. Extracellular matrix proteins confer cell Adhesion-Mediated drug resistance through integrin alpha (v) in glioblastoma cells. Front Cell Dev Biol. 2021;9:616580. https:\/\/doi.org\/10.3389\/fcell.2021.616580.","journal-title":"Front Cell Dev Biol"},{"key":"4188_CR61","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3892\/ijo.2014.2265","volume":"44","author":"Y Nakagawa","year":"2014","unstructured":"Nakagawa Y, et al. Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells. Int J Oncol. 2014;44:1376\u201384. https:\/\/doi.org\/10.3892\/ijo.2014.2265.","journal-title":"Int J Oncol"},{"key":"4188_CR62","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1586\/17474086.2014.958464","volume":"7","author":"A Isidori","year":"2014","unstructured":"Isidori A, et al. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Rev Hematol. 2014;7:807\u201318. https:\/\/doi.org\/10.1586\/17474086.2014.958464.","journal-title":"Expert Rev Hematol"},{"key":"4188_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26951-z","volume":"12","author":"SM Tirier","year":"2021","unstructured":"Tirier SM, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021;12:6960. https:\/\/doi.org\/10.1038\/s41467-021-26951-z.","journal-title":"Nat Commun"},{"key":"4188_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004863","author":"S Peters","year":"2022","unstructured":"Peters S, Paz-Ares L, Herbst RS, Reck M. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-004863.","journal-title":"J Immunother Cancer"},{"key":"4188_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin H, et al. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol. 2024;17:31. https:\/\/doi.org\/10.1186\/s13045-024-01544-7.","journal-title":"J Hematol Oncol"},{"key":"4188_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01990-4","volume":"23","author":"M Kundu","year":"2024","unstructured":"Kundu M, et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Mol Cancer. 2024;23:92. https:\/\/doi.org\/10.1186\/s12943-024-01990-4.","journal-title":"Mol Cancer"},{"key":"4188_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092018","author":"FM Uckun","year":"2021","unstructured":"Uckun FM. Overcoming the immunosuppressive tumor microenvironment in multiple myeloma. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13092018.","journal-title":"Cancers (Basel)"},{"key":"4188_CR68","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1111\/bph.14776","volume":"176","author":"S Trousil","year":"2019","unstructured":"Trousil S, et al. Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation. Br J Pharmacol. 2019;176:3712\u201322. https:\/\/doi.org\/10.1111\/bph.14776.","journal-title":"Br J Pharmacol"},{"key":"4188_CR69","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1039\/d2bm00650b","volume":"10","author":"LR Tian","year":"2022","unstructured":"Tian LR, et al. Nanodrug regulates lactic acid metabolism to reprogram the immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. Biomater Sci. 2022;10:3892\u2013900. https:\/\/doi.org\/10.1039\/d2bm00650b.","journal-title":"Biomater Sci"},{"key":"4188_CR70","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1111\/cas.15087","volume":"112","author":"S Ikeda","year":"2021","unstructured":"Ikeda S, Tagawa H. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma. Cancer Sci. 2021;112:3995\u20134004. https:\/\/doi.org\/10.1111\/cas.15087.","journal-title":"Cancer Sci"},{"key":"4188_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/cells12071030","author":"SD Alipoor","year":"2023","unstructured":"Alipoor SD, Chang H. Exosomal miRNAs in the tumor microenvironment of multiple myeloma. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12071030.","journal-title":"Cells"},{"key":"4188_CR72","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/1759-7714.14929","volume":"14","author":"C Wang","year":"2023","unstructured":"Wang C, et al. Abnormal activation of NF\u2010\u03baB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid\u2010derived suppressor cells to shape the immunosuppressive tumor immune microenvironment. Thorac Cancer. 2023;14:1843\u201356. https:\/\/doi.org\/10.1111\/1759-7714.14929.","journal-title":"Thorac Cancer"},{"key":"4188_CR73","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1158\/0008-5472.CAN-22-3481","volume":"83","author":"PSY Chong","year":"2023","unstructured":"Chong PSY, et al. Histone methyltransferase NSD2 activates PKC\u03b1 to drive metabolic reprogramming and lenalidomide resistance in multiple myeloma. Cancer Res. 2023;83:3414\u201327. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-3481.","journal-title":"Cancer Res"},{"key":"4188_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.591342","volume":"10","author":"S Wu","year":"2020","unstructured":"Wu S, Kuang H, Ke J, Pi M, Yang DH. Metabolic reprogramming induces immune cell dysfunction in the tumor microenvironment of multiple myeloma. Front Oncol. 2020;10:591342. https:\/\/doi.org\/10.3389\/fonc.2020.591342.","journal-title":"Front Oncol"},{"key":"4188_CR75","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1007\/s00277-024-05843-4","volume":"103","author":"HY Xue","year":"2024","unstructured":"Xue HY, Wei F. TGF-beta: an active participant in the immune and metabolic microenvironment of multiple myeloma: TGF-beta in the microenvironment of multiple myeloma. Ann Hematol. 2024;103:4351\u201362. https:\/\/doi.org\/10.1007\/s00277-024-05843-4.","journal-title":"Ann Hematol"},{"key":"4188_CR76","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13388","volume":"56","author":"A Barbato","year":"2023","unstructured":"Barbato A, et al. Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma. Cell Prolif. 2023;56:e13388. https:\/\/doi.org\/10.1111\/cpr.13388.","journal-title":"Cell Prolif"},{"key":"4188_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061682","author":"P Weir","year":"2023","unstructured":"Weir P, Donaldson D, McMullin MF, Crawford L. Metabolic alterations in multiple myeloma: from oncogenesis to proteasome inhibitor resistance. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15061682.","journal-title":"Cancers (Basel)"},{"key":"4188_CR78","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/path.4712","volume":"239","author":"J Wang","year":"2016","unstructured":"Wang J, et al. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression. J Pathol. 2016;239:162\u201373. https:\/\/doi.org\/10.1002\/path.4712.","journal-title":"J Pathol"},{"key":"4188_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1015402","volume":"12","author":"V Raimondi","year":"2022","unstructured":"Raimondi V, et al. Metabolic features of myeloma cells in the context of bone microenvironment: implication for the pathophysiology and clinic of myeloma bone disease. Front Oncol. 2022;12:1015402. https:\/\/doi.org\/10.3389\/fonc.2022.1015402.","journal-title":"Front Oncol"},{"key":"4188_CR80","doi-asserted-by":"publisher","first-page":"C750","DOI":"10.1152\/ajpcell.00575.2020","volume":"320","author":"A Biswas","year":"2021","unstructured":"Biswas A, De S. Drivers of dynamic intratumor heterogeneity and phenotypic plasticity. Am J Physiol Cell Physiol. 2021;320:C750\u201360. https:\/\/doi.org\/10.1152\/ajpcell.00575.2020.","journal-title":"Am J Physiol Cell Physiol"},{"key":"4188_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00933-y","volume":"13","author":"SR Choudhury","year":"2020","unstructured":"Choudhury SR, et al. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. J Hematol Oncol. 2020;13:108. https:\/\/doi.org\/10.1186\/s13045-020-00933-y.","journal-title":"J Hematol Oncol"},{"key":"4188_CR82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2019.01.012","volume":"446","author":"H Yan","year":"2019","unstructured":"Yan H, et al. Multiple myeloma cell-derived IL-32\u03b3 increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression. Cancer Lett. 2019;446:38\u201348. https:\/\/doi.org\/10.1016\/j.canlet.2019.01.012.","journal-title":"Cancer Lett"},{"key":"4188_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00071","volume":"7","author":"S Bhatia","year":"2020","unstructured":"Bhatia S, Wang P, Toh A, Thompson EW. New insights into the role of phenotypic plasticity and EMT in driving cancer progression. Front Mol Biosci. 2020;7:71. https:\/\/doi.org\/10.3389\/fmolb.2020.00071.","journal-title":"Front Mol Biosci"},{"key":"4188_CR84","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood.2020007081","volume":"137","author":"S Gooding","year":"2021","unstructured":"Gooding S, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021;137:232\u20137. https:\/\/doi.org\/10.1182\/blood.2020007081.","journal-title":"Blood"},{"key":"4188_CR85","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.3892\/or.2019.6968","volume":"41","author":"L Wang","year":"2019","unstructured":"Wang L, Lin N, Li Y. The PI3K\/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma. Oncol Rep. 2019;41:1678\u201390. https:\/\/doi.org\/10.3892\/or.2019.6968.","journal-title":"Oncol Rep"},{"key":"4188_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/biom10050696","author":"D Tibullo","year":"2020","unstructured":"Tibullo D, et al. Mitochondrial functions, energy metabolism and protein glycosylation are interconnected processes mediating resistance to bortezomib in multiple myeloma cells. Biomolecules. 2020. https:\/\/doi.org\/10.3390\/biom10050696.","journal-title":"Biomolecules"},{"key":"4188_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Niu T, Tong A. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024;5:25. https:\/\/doi.org\/10.1186\/s43556-024-00188-w.","journal-title":"Mol Biomed"},{"key":"4188_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194787","author":"J Ackley","year":"2021","unstructured":"Ackley J, et al. Keeping myeloma in check: the past, present and future of immunotherapy in multiple myeloma. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13194787.","journal-title":"Cancers (Basel)"},{"key":"4188_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1038329","volume":"12","author":"LY Chen","year":"2022","unstructured":"Chen LY, Gooding S. Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma. Front Oncol. 2022;12:1038329. https:\/\/doi.org\/10.3389\/fonc.2022.1038329.","journal-title":"Front Oncol"},{"key":"4188_CR90","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1172\/JCI129205","volume":"130","author":"SA Minnie","year":"2020","unstructured":"Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130:1565\u201375. https:\/\/doi.org\/10.1172\/JCI129205.","journal-title":"J Clin Invest"},{"key":"4188_CR91","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","volume":"34","author":"CC Bjorklund","year":"2020","unstructured":"Bjorklund CC, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020;34:1197\u2013201. https:\/\/doi.org\/10.1038\/s41375-019-0620-8.","journal-title":"Leukemia"},{"key":"4188_CR92","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2020-137667","volume":"136","author":"M Amatangelo","year":"2020","unstructured":"Amatangelo M, et al. Preclinical and translational data support development of iberdomide in combination with CD38- and SLAMF7-directed monoclonal antibodies: evidence for rational combinations. Blood. 2020;136:9\u201310. https:\/\/doi.org\/10.1182\/blood-2020-137667.","journal-title":"Blood"},{"key":"4188_CR93","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1182\/blood-2021-151542","volume":"138","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, et al. Large-scale mass cytometry reveals significant activation of innate and adaptive immunity in bone marrow tumor microenvironment of iberdomide-treated myeloma patients. Blood. 2021;138:730. https:\/\/doi.org\/10.1182\/blood-2021-151542.","journal-title":"Blood"},{"key":"4188_CR94","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.39","volume":"7","author":"J Schutt","year":"2024","unstructured":"Schutt J, Brinkert K, Plis A, Schenk T, Brioli A. Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review. Cancer Drug Resist. 2024;7:26. https:\/\/doi.org\/10.20517\/cdr.2024.39.","journal-title":"Cancer Drug Resist"},{"key":"4188_CR95","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/phar.1871","volume":"37","author":"C Chung","year":"2017","unstructured":"Chung C. Role of immunotherapy in targeting the bone marrow microenvironment in multiple myeloma: an evolving therapeutic strategy. Pharmacotherapy. 2017;37:129\u201343. https:\/\/doi.org\/10.1002\/phar.1871.","journal-title":"Pharmacotherapy"},{"key":"4188_CR96","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-021-01109-y","volume":"14","author":"CT Su","year":"2021","unstructured":"Su CT, Ye JC. Emerging therapies for relapsed\/refractory multiple myeloma: CAR-T and beyond. J Hematol Oncol. 2021;14:115. https:\/\/doi.org\/10.1186\/s13045-021-01109-y.","journal-title":"J Hematol Oncol"},{"key":"4188_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147627","author":"P Neumeister","year":"2022","unstructured":"Neumeister P, Schulz E, Pansy K, Szmyra M, Deutsch AJ. Targeting the microenvironment for treating multiple myeloma. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23147627.","journal-title":"Int J Mol Sci"},{"key":"4188_CR98","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","volume":"2","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Discov. 2021;2:302\u201318. https:\/\/doi.org\/10.1158\/2643-3230.BCD-20-0227.","journal-title":"Blood Cancer Discov"},{"key":"4188_CR99","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985\u20131005. https:\/\/doi.org\/10.1038\/s41375-020-0734-z.","journal-title":"Leukemia"},{"key":"4188_CR100","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","volume":"4","author":"J Derrien","year":"2023","unstructured":"Derrien J, et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat Cancer. 2023;4:1536\u201343. https:\/\/doi.org\/10.1038\/s43018-023-00625-9.","journal-title":"Nat Cancer"},{"key":"4188_CR101","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood.2024026622","volume":"146","author":"S Ma","year":"2025","unstructured":"Ma S, et al. Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma. Blood. 2025;146:178\u201390. https:\/\/doi.org\/10.1182\/blood.2024026622.","journal-title":"Blood"},{"key":"4188_CR102","doi-asserted-by":"publisher","first-page":"e365","DOI":"10.1016\/S2352-3026(25)00048-1","volume":"12","author":"J Xia","year":"2025","unstructured":"Xia J, et al. Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2025;12:e365\u201375. https:\/\/doi.org\/10.1016\/S2352-3026(25)00048-1.","journal-title":"Lancet Haematol"},{"key":"4188_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol. 2023;14:1101495. https:\/\/doi.org\/10.3389\/fimmu.2023.1101495.","journal-title":"Front Immunol"},{"key":"4188_CR104","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2174\/1568009617666170906170348","volume":"17","author":"D Atanackovic","year":"2017","unstructured":"Atanackovic D, Luetkens T, Radhakrishnan S, Kroger N. Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of multiple myeloma. Curr Cancer Drug Targets. 2017;17:839\u201345. https:\/\/doi.org\/10.2174\/1568009617666170906170348.","journal-title":"Curr Cancer Drug Targets"},{"key":"4188_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"DR Wang","year":"2022","unstructured":"Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022;7:331. https:\/\/doi.org\/10.1038\/s41392-022-01136-2.","journal-title":"Signal Transduct Target Ther"},{"key":"4188_CR106","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.18.01998","volume":"37","author":"C Lebbe","year":"2019","unstructured":"Lebbe C, et al. Evaluation of two dosing regimens for Nivolumab in combination with Ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 trial. J Clin Oncol. 2019;37:867\u201375. https:\/\/doi.org\/10.1200\/JCO.18.01998.","journal-title":"J Clin Oncol"},{"key":"4188_CR107","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","volume":"4","author":"S Tan","year":"2022","unstructured":"Tan S, Day D, Nicholls SJ, Segelov E. Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 2022;4:579\u201397. https:\/\/doi.org\/10.1016\/j.jaccao.2022.09.004.","journal-title":"JACC CardioOncol"},{"key":"4188_CR108","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.18.00766","volume":"37","author":"SM Ansell","year":"2019","unstructured":"Ansell SM, et al. Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37:481\u20139. https:\/\/doi.org\/10.1200\/JCO.18.00766.","journal-title":"J Clin Oncol"},{"key":"4188_CR109","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ajh.25659","volume":"95","author":"AF Herrera","year":"2020","unstructured":"Herrera AF, et al. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. Am J Hematol. 2020;95:18\u201327. https:\/\/doi.org\/10.1002\/ajh.25659.","journal-title":"Am J Hematol"},{"key":"4188_CR110","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","volume":"18","author":"NL Syn","year":"2017","unstructured":"Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18:e731\u201341. https:\/\/doi.org\/10.1016\/S1470-2045(17)30607-1.","journal-title":"Lancet Oncol"},{"key":"4188_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773168","volume":"12","author":"Q Wang","year":"2021","unstructured":"Wang Q, et al. What happens to the immune microenvironment after PD-1 inhibitor therapy? Front Immunol. 2021;12:773168. https:\/\/doi.org\/10.3389\/fimmu.2021.773168.","journal-title":"Front Immunol"},{"key":"4188_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.580140","volume":"8","author":"Q Huang","year":"2020","unstructured":"Huang Q, Lei Y, Li X, Guo F, Liu M. A highlight of the mechanisms of immune checkpoint blocker resistance. Front Cell Dev Biol. 2020;8:580140. https:\/\/doi.org\/10.3389\/fcell.2020.580140.","journal-title":"Front Cell Dev Biol"},{"key":"4188_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:155. https:\/\/doi.org\/10.1186\/s12943-019-1091-2.","journal-title":"Mol Cancer"},{"key":"4188_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121285","volume":"14","author":"Z Guo","year":"2023","unstructured":"Guo Z, Zhang R, Yang AG, Zheng G. Diversity of immune checkpoints in cancer immunotherapy. Front Immunol. 2023;14:1121285. https:\/\/doi.org\/10.3389\/fimmu.2023.1121285.","journal-title":"Front Immunol"},{"key":"4188_CR115","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-19-2925","volume":"27","author":"J Sun","year":"2021","unstructured":"Sun J, Lu Q, Sanmamed MF, Wang J. Siglec-15 as an emerging target for next-generation cancer immunotherapy. Clin Cancer Res. 2021;27:680\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2925.","journal-title":"Clin Cancer Res"},{"key":"4188_CR116","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.coph.2016.02.013","volume":"28","author":"S Gooding","year":"2016","unstructured":"Gooding S, Edwards CM. New approaches to targeting the bone marrow microenvironment in multiple myeloma. Curr Opin Pharmacol. 2016;28:43\u20139. https:\/\/doi.org\/10.1016\/j.coph.2016.02.013.","journal-title":"Curr Opin Pharmacol"},{"key":"4188_CR117","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood-2015-08-665679","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, et al. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016;127:1896\u2013906. https:\/\/doi.org\/10.1182\/blood-2015-08-665679.","journal-title":"Blood"},{"key":"4188_CR118","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/onc.2008.385","volume":"28","author":"K Noborio-Hatano","year":"2009","unstructured":"Noborio-Hatano K, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009;28:231\u201342. https:\/\/doi.org\/10.1038\/onc.2008.385.","journal-title":"Oncogene"},{"key":"4188_CR119","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18485","volume":"12","author":"J Roosma","year":"2024","unstructured":"Roosma J. A comprehensive review of oncogenic Notch signaling in multiple myeloma. PeerJ. 2024;12:e18485. https:\/\/doi.org\/10.7717\/peerj.18485.","journal-title":"PeerJ"},{"key":"4188_CR120","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.canlet.2015.11.028","volume":"380","author":"JM Bouyssou","year":"2016","unstructured":"Bouyssou JM, Ghobrial IM, Roccaro AM. Targeting SDF-1 in multiple myeloma tumor microenvironment. Cancer Lett. 2016;380:315\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2015.11.028.","journal-title":"Cancer Lett"},{"key":"4188_CR121","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2024.5468","author":"R Xing","year":"2025","unstructured":"Xing R. Clinical updates of B\u2011cell maturation antigen\u2011targeted therapy in multiple myeloma (MM) and relapsed\/refractory MM (review). Int J Mol Med. 2025. https:\/\/doi.org\/10.3892\/ijmm.2024.5468.","journal-title":"Int J Mol Med"},{"key":"4188_CR122","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.molimm.2018.08.019","volume":"101","author":"K Venken","year":"2018","unstructured":"Venken K, et al. Checkpoint inhibition in the treatment of multiple myeloma: a way to boost innate-like T cell anti-tumor function? Mol Immunol. 2018;101:521\u20136. https:\/\/doi.org\/10.1016\/j.molimm.2018.08.019.","journal-title":"Mol Immunol"},{"key":"4188_CR123","doi-asserted-by":"publisher","first-page":"e0267475","DOI":"10.1371\/journal.pone.0267475","volume":"17","author":"X Zhang","year":"2022","unstructured":"Zhang X, et al. Vgamma9Vdelta2 T cells expressing a BCMA-Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth. PLoS ONE. 2022;17:e0267475. https:\/\/doi.org\/10.1371\/journal.pone.0267475.","journal-title":"PLoS ONE"},{"key":"4188_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12081999","author":"C Giallongo","year":"2020","unstructured":"Giallongo C. Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12081999.","journal-title":"Cancers (Basel)"},{"key":"4188_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.760382","volume":"11","author":"FM Uckun","year":"2021","unstructured":"Uckun FM. Dual targeting of multiple myeloma stem cells and myeloid-derived suppressor cells for treatment of chemotherapy-resistant multiple myeloma. Front Oncol. 2021;11:760382. https:\/\/doi.org\/10.3389\/fonc.2021.760382.","journal-title":"Front Oncol"},{"key":"4188_CR126","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2147\/OTT.S102756","volume":"10","author":"RE Steiner","year":"2017","unstructured":"Steiner RE, Manasanch EE. Carfilzomib boosted combination therapy for relapsed multiple myeloma. Onco Targets Ther. 2017;10:895\u2013907. https:\/\/doi.org\/10.2147\/OTT.S102756.","journal-title":"Onco Targets Ther"},{"key":"4188_CR127","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.semcancer.2010.04.003","volume":"20","author":"BZ Katz","year":"2010","unstructured":"Katz BZ. Adhesion molecules\u2013the lifelines of multiple myeloma cells. Semin Cancer Biol. 2010;20:186\u201395. https:\/\/doi.org\/10.1016\/j.semcancer.2010.04.003.","journal-title":"Semin Cancer Biol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04188-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04188-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04188-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:41:06Z","timestamp":1771425666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04188-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4188"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04188-4","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}